Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) for the Treatment of Factor Xa Inhibitor-Associated Acute Major Bleeding
The product of a joint development programme between the Swiss pharmaceutical company Basilea Pharmaceutica AG and Cilag AG International (a Johnson & Johnson company), ceftobiprole medocaril (BAL5788) is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.
Defitelio (defibrotide sodium) is an injectable drug developed by Jazz Pharmaceuticals, for the treatment of hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome, in adults and children with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
Humira (adalimumab) is a monoclonal antibody indicated for the treatment of more than ten indications, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa (HS), and uveitis.
KERENDIA® (finerenone) is a first-in-class, nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the progression of chronic kidney disease, risk of kidney failure and risk of cardiovascular disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
Kesimpta® (ofatumumab) is the first and only self-administered, targeted B-cell therapy indicated for the treatment of patients with relapsing multiple sclerosis (RMS) including clinically isolated syndrome (CIS), relapsing-remitting (RRMS), and active secondary progressive multiple sclerosis (SPMS).
Lutathera (lutetium Lu 177 dotatate) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumours
Nexavar is an oral anti-cancer agent that blocks cell proliferation and tumour angiogenesis. Developed by Bayer Healthcare with Onyx Pharmaceuticals, the drug obstructs the receptor tyrosine kinases – vascular endothelial growth factor receptor (VEGFR) VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR B), KIT, fms-related tyrosine kinase 3 (FLT-3) and RET – along the signalling pathways.
Onpattro (patisiran) for the Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Rybrevant (amivantamab-vmjw) is the first fully-human bispecific antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has advanced on or after platinum-based chemotherapy.
Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that results in mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping.
ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well as granulomatosis with polyangiitis and microscopic polyangiitis.
Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic drug indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It was developed by Forest Laboratories in collaboration with Spanish company Almirall.
The product of a joint development programme between Bayer and Johnson & Johnson, Xarelto (rivaroxaban) is a new oral anticoagulant. It is indicated for the primary prevention and treatment of venous thromboembolism (VTE) following orthopaedic surgery. Clinical trials are also ongoing to evaluate Xarelto (rivaroxaban) for stroke prevention in patients with atrial fibrillation and acute coronary syndrome.
XYWAV (calcium, magnesium, potassium, and sodium oxybates) for the Treatment of Cataplexy and Narcolepsy, USA
Zilretta (triamcinolone acetonide extended-release injectable suspension) for the Treatment of Osteoarthritis Knee Pain
Zioptan (tafluprost ophthalmic solution) was developed by Santen Pharmaceutical in collaboration with Merck. The drug is indicated for the reduction of elevated intraocular pressure (IOP). In February 2012, Zioptan received approval for the reduction of IOP in patients suffering from ocular hypertension or open-angle glaucoma.